Update on Biologics: Report From the AAD Meeting

At the 73rd Annual Meeting of the American Academy of Dermatology in San Francisco, California, Dr. Jashin J. Wu spoke about the risk for cancer, infection, and MACE (major adverse cardiovascular events) in psoriasis patients on a biologic. Dr. Wu provides an overview of the data evaluating biologics versus nonbiologic therapies. He discusses biologics such as infliximab, ustekinumab, etanercept, and adalimumab, as well as tumor necrosis factor inhibitors.

At the 73rd Annual Meeting of the American Academy of Dermatology in San Francisco, California, Dr. Jashin J. Wu spoke about the risk for cancer, infection, and MACE (major adverse cardiovascular events) in psoriasis patients on a biologic. Dr. Wu provides an overview of the data evaluating biologics versus nonbiologic therapies. He discusses biologics such as infliximab, ustekinumab, etanercept, and adalimumab, as well as tumor necrosis factor inhibitors.

At the 73rd Annual Meeting of the American Academy of Dermatology in San Francisco, California, Dr. Jashin J. Wu spoke about the risk for cancer, infection, and MACE (major adverse cardiovascular events) in psoriasis patients on a biologic. Dr. Wu provides an overview of the data evaluating biologics versus nonbiologic therapies. He discusses biologics such as infliximab, ustekinumab, etanercept, and adalimumab, as well as tumor necrosis factor inhibitors.